A Study Testing the Safety of CD19-Targeted CAR T-Cell Therapy in Children and Young Adults with Relapsed or Refractory B-Cell Cancers

1 1

What is this study about?

This study is looking at two types of cancer that affect certain white blood cells. The first is B-cell precursor ALL, which is a cancer where the bone marrow makes too many immature white blood cells. The second is B-cell Non Hodgkin Lymphoma, which is a cancer that starts in white blood cells called lymphocytes and can affect lymph nodes and other parts of the body. Both of these cancers have either come back after previous treatment or have not responded to treatment. The study will use a treatment called MB-huCART19.1, which is a type of therapy where a patient’s own immune cells are collected and modified in a laboratory to better recognize and attack cancer cells that have a specific marker called CD19 on their surface. These modified cells, known as CAR T-cells, are then given back to the patient through intravenous infusion, which means the cells are delivered directly into a vein.

The purpose of this study is to find out the safest dose of these modified cells that can be given to patients and to see how well the treatment works. The study will look at how many patients experience serious side effects within 28 days after receiving the treatment, which will help determine the best dose to use in the next part of the study. The study will also measure how well the treatment works by checking if the cancer responds to the treatment and how long patients remain free from disease.

During the study, patients will first have their own immune cells collected. These cells will then be modified in a laboratory to target the cancer cells. Before receiving the modified cells back, patients may receive chemotherapy to prepare their body for the treatment. After the modified cells are given through an infusion into a vein, patients will be monitored closely for side effects and to see how well the treatment is working. The study will follow patients for up to 12 months to track their progress and see if the cancer comes back. This study is for children and young adults between 1 and 45 years of age who have tried other treatments that did not work or who cannot receive other standard treatments.

1 Enrollment and Initial Assessment

Your medical condition will be confirmed as relapsed or refractory CD19-positive blood cancer, which includes either B-cell precursor acute lymphoblastic leukemia (a type of blood cancer affecting white blood cells) or B-cell Non-Hodgkin Lymphoma (a cancer of the lymphatic system).

Your doctor will verify that you have measurable disease, meaning either at least one tumor that can be measured or at least 0.1% of cancer cells in your bone marrow.

Your overall health and ability to perform daily activities will be assessed through a performance score.

If you are of childbearing potential, you will need to agree to use highly effective birth control methods starting from the first treatment and continuing for 12 months after receiving the last study treatment.

You will need to agree not to breastfeed for 12 months after receiving the last study treatment.

You will need to agree not to donate blood or organs after receiving the treatment with huCAR19 T-cells (modified immune cells designed to target cancer cells).

2 Treatment with MB-huCART19.1

You will receive MB-huCART19.1, which is a treatment involving modified immune cells called CAR T-cells. These cells are designed to recognize and attack cancer cells that have a protein called CD19 on their surface.

The treatment will be administered as an intravenous infusion, meaning it will be given directly into your vein.

The dose you receive will be determined based on the phase of the study and the safety observations from previous patients. The study aims to find the recommended phase 2 dose, which is the safest and most effective amount.

3 Monitoring for Side Effects (First 28 Days)

During the first 28 days after receiving the CAR T-cell infusion, you will be closely monitored for any serious side effects called Dose Limiting Toxicity.

Your medical team will assess your response to the treatment and check for any complications.

4 Disease Response Assessment at Day 28

At day 28 after the infusion, your response to treatment will be evaluated.

If you have B-cell precursor acute lymphoblastic leukemia, your doctor will check for MRD-negative complete remission, which means no cancer cells can be detected even with very sensitive tests.

Your doctor will also check for B-cell aplasia, which means a very low number of B-cells in your blood (less than 5 B-cells per microliter). This is actually a sign that the CAR T-cells are working, as they target cells with the CD19 protein, which includes both cancer cells and normal B-cells.

5 Disease Response Assessment at Day 90

If you have B-cell Non-Hodgkin Lymphoma, your response to treatment will be assessed at day 90 after the infusion.

Your doctor will determine the overall response rate according to established criteria, which includes complete disappearance of cancer (complete response) or significant reduction in tumor size (partial response).

6 Monitoring for B-Cell Recovery

Your medical team will monitor when your normal B-cells begin to recover after treatment.

B-cell recovery is defined as having at least 10 CD19-positive B-cells per microliter in your blood, or at least 1% CD19-positive B-cells in your bone marrow.

This recovery will need to be confirmed with a second test performed at least 2 weeks after the first test showing recovery.

7 Follow-Up at 6 Months

At 6 months after the CAR T-cell infusion, your medical team will assess several outcomes.

Your doctor will evaluate event-free survival, which means the time you have lived without the cancer returning or worsening.

Your overall survival will be documented.

The medical team will assess whether the cancer has returned (cumulative incidence of relapse).

8 Follow-Up at 12 Months

At 12 months after the CAR T-cell infusion, your medical team will perform another comprehensive assessment.

Your doctor will evaluate event-free survival, which means the time you have lived without the cancer returning or worsening.

Your overall survival will be documented.

The medical team will assess whether the cancer has returned (cumulative incidence of relapse).

This marks the end of the primary study period, though your doctor may continue to monitor your health beyond this point.

Who Can Join the Study?

You must be between 1 and 45 years of age
For the first part of the study, the first three patients must be between 12 and 45 years old. After that, patients of any age between 1 and 45 years can join once a specific treatment response is seen in earlier patients
You must have a blood cancer that has either come back after treatment (relapsed) or did not respond to treatment (refractory), and your cancer cells must have a protein called CD19 on their surface
Your disease must be measurable, meaning doctors can see at least one area of disease or find at least 0.1% of cancer cells called blasts in your bone marrow (the soft tissue inside your bones where blood cells are made)
You must have already tried all standard treatments that could potentially cure your disease, or you cannot receive those treatments for medical reasons
You must have an adequate performance score, which means you are healthy enough to participate in the study
If you are able to have children, you must be willing to use very effective birth control methods from the start of chemotherapy until 12 months after receiving the last study treatment
If you are able to breastfeed, you must agree not to breastfeed until 12 months after receiving the last study treatment
You must agree not to donate blood or organs after receiving the study treatment
You must provide written informed consent, which means you understand the study and agree to participate by signing the required documents

Who Cannot Join the Study?

The source data does not provide specific exclusion criteria (reasons why a patient cannot participate) for this clinical trial
Without detailed exclusion criteria information, it is not possible to list the specific conditions or situations that would prevent participation in this study
Exclusion criteria typically include things like certain other medical conditions, previous treatments, laboratory test results, or medications that would make it unsafe or inappropriate for someone to join the trial
In this case, the trial involves CAR T-cell therapy, which is a treatment where a patient’s own immune cells are modified in a laboratory to help fight cancer cells
The study focuses on patients with B-cell precursor ALL (a type of blood cancer affecting white blood cells) and B-cell Non Hodgkin Lymphoma (a type of cancer affecting the lymphatic system)

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Universitair Medisch Centrum Utrecht	Utrecht	The Netherlands
Prinses Maxima Centrum voor Kinderoncologie B.V.	Utrecht	The Netherlands

Trial status

Country	Status	Recruitment Start
The Netherlands	Not yet recruiting	01.01.2026

Trial locations

Investigated drugs:

MB-HUCART19.1

huCAR19 is a type of treatment called CAR T-cell therapy. This is a personalized cancer treatment where a patient’s own immune cells (called T-cells) are collected and modified in a laboratory to recognize and attack cancer cells. Specifically, these modified cells are designed to target a protein called CD19 that is found on the surface of certain cancer cells. Once the cells are prepared, they are given back to the patient through an infusion to help fight their cancer. This treatment is being made at the point-of-care, meaning it is prepared closer to where the patient is being treated.

B-cell precursor acute lymphoblastic leukemia – This is a type of blood cancer that affects the white blood cells called B-cell lymphocytes. The disease begins in the bone marrow where blood cells are made. Abnormal immature B-cells multiply rapidly and crowd out healthy blood cells. These cancer cells cannot function properly to fight infections. The disease progresses quickly as the abnormal cells accumulate in the blood and bone marrow. Without intervention, the cancer cells can spread to other organs including the lymph nodes, liver, and spleen.

B-cell non-Hodgkin lymphoma – This is a cancer that develops in the lymphatic system, specifically affecting B-cells which are a type of white blood cell. The disease occurs when B-cells grow abnormally and uncontrollably, forming tumors in the lymph nodes or other organs. These cancerous cells can accumulate in various parts of the body including the lymph nodes, spleen, bone marrow, and other organs. The disease can progress at different rates depending on the specific subtype. As the cancer advances, the abnormal cells interfere with the normal function of the immune system. The cancerous B-cells can spread through the lymphatic system to different areas of the body.

Trial ID:

2023-507597-40-00

Protocol code:

SP_MB21PAC

NCT ID:

NCT07020260

Trial Phase:

Human Pharmacology (Phase I) – Other

Other Trials to Consider

#1 Clinical Trials Search in Europe

A Study Testing the Safety of CD19-Targeted CAR T-Cell Therapy in Children and Young Adults with Relapsed or Refractory B-Cell Cancers

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?